HRP20170307T1 - NOVI DERIVATI CIKLOHEKSILAMINA KOJI POSJEDUJU DJELOVANJA AGONISTA ß2 ADRENERGIČKOG RECEPTORA I ANTAGONISTA M3 MUSKARINSKOG RECEPTORA - Google Patents
NOVI DERIVATI CIKLOHEKSILAMINA KOJI POSJEDUJU DJELOVANJA AGONISTA ß2 ADRENERGIČKOG RECEPTORA I ANTAGONISTA M3 MUSKARINSKOG RECEPTORA Download PDFInfo
- Publication number
- HRP20170307T1 HRP20170307T1 HRP20170307TT HRP20170307T HRP20170307T1 HR P20170307 T1 HRP20170307 T1 HR P20170307T1 HR P20170307T T HRP20170307T T HR P20170307TT HR P20170307 T HRP20170307 T HR P20170307T HR P20170307 T1 HRP20170307 T1 HR P20170307T1
- Authority
- HR
- Croatia
- Prior art keywords
- hydroxy
- amino
- methyl
- group
- ethyl
- Prior art date
Links
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 title 1
- 239000000048 adrenergic agonist Substances 0.000 title 1
- 150000003946 cyclohexylamines Chemical class 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 239000003149 muscarinic antagonist Substances 0.000 title 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 36
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 29
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 17
- -1 {[2-chloro-4-({[(2R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydro-quinoline-5- yl)ethyl]amino}methyl)-5-methoxyphenyl]amino}carbonyl Chemical group 0.000 claims 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 14
- 125000001424 substituent group Chemical group 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims 5
- 125000001544 thienyl group Chemical group 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 229910052801 chlorine Inorganic materials 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 3
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- FVEJUHUCFCAYRP-UHFFFAOYSA-N 2-hydroxy-2,2-dithiophen-2-ylacetic acid Chemical compound C=1C=CSC=1C(O)(C(=O)O)C1=CC=CS1 FVEJUHUCFCAYRP-UHFFFAOYSA-N 0.000 claims 1
- WCRHWWWLTNWHQS-ABCZBHHISA-N C12=CC=CC=C2OC2=CC=CC=C2C1(C)C(=O)O[C@H](CC1)CC[C@@H]1N(C)CCCCCCCCCNC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 Chemical compound C12=CC=CC=C2OC2=CC=CC=C2C1(C)C(=O)O[C@H](CC1)CC[C@@H]1N(C)CCCCCCCCCNC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 WCRHWWWLTNWHQS-ABCZBHHISA-N 0.000 claims 1
- AHZPWGGWOSEDTP-WBXFWKJNSA-N COc1cc(NC(=O)CCN(C)[C@H]2CC[C@@H](CC2)OC(=O)C(O)(c2cccs2)c2cccs2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 Chemical compound COc1cc(NC(=O)CCN(C)[C@H]2CC[C@@H](CC2)OC(=O)C(O)(c2cccs2)c2cccs2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 AHZPWGGWOSEDTP-WBXFWKJNSA-N 0.000 claims 1
- 208000020446 Cardiac disease Diseases 0.000 claims 1
- DEFIGYIWVLTMLO-GHAOVRLMSA-N F.CC(Cc1ccc(OCCCN(C)[C@H]2CC[C@@H](CC2)OC(=O)C(O)(c2cccs2)c2cccs2)cc1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 Chemical compound F.CC(Cc1ccc(OCCCN(C)[C@H]2CC[C@@H](CC2)OC(=O)C(O)(c2cccs2)c2cccs2)cc1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 DEFIGYIWVLTMLO-GHAOVRLMSA-N 0.000 claims 1
- WGRRMDFUMITLJB-ZJTCZQGWSA-N F.CN(CCC(=O)Nc1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1Cl)[C@H]1CC[C@@H](CC1)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound F.CN(CCC(=O)Nc1ccc(CNC[C@H](O)c2ccc(O)c3[nH]c(=O)ccc23)cc1Cl)[C@H]1CC[C@@H](CC1)OC(=O)C(O)(c1cccs1)c1cccs1 WGRRMDFUMITLJB-ZJTCZQGWSA-N 0.000 claims 1
- PVDQCNRZXDIHDO-PSDISIQPSA-N F.O([C@H]1CC[C@@H](CC1)N(C)CCCCOC=1C=C(C(=CC=1Cl)CNC[C@H](O)C=1C=2C=CC(=O)NC=2C(O)=CC=1)OC)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 Chemical compound F.O([C@H]1CC[C@@H](CC1)N(C)CCCCOC=1C=C(C(=CC=1Cl)CNC[C@H](O)C=1C=2C=CC(=O)NC=2C(O)=CC=1)OC)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 PVDQCNRZXDIHDO-PSDISIQPSA-N 0.000 claims 1
- LPRBLDKUDJHOFD-XFPMNCHFSA-N F.O([C@H]1CC[C@@H](CC1)N(C)CCCOC=1C=C(C(=CC=1Cl)CNC[C@H](O)C=1C=2C=CC(=O)NC=2C(O)=CC=1)OC)C(C(O)=O)(C=1SC=CC=1)C1=CC=CS1 Chemical compound F.O([C@H]1CC[C@@H](CC1)N(C)CCCOC=1C=C(C(=CC=1Cl)CNC[C@H](O)C=1C=2C=CC(=O)NC=2C(O)=CC=1)OC)C(C(O)=O)(C=1SC=CC=1)C1=CC=CS1 LPRBLDKUDJHOFD-XFPMNCHFSA-N 0.000 claims 1
- CNLYMTUKZNDEKW-RGHVVQLISA-N F.O([C@H]1CC[C@@H](CC1)N(CCCOCCCCCCNC[C@H](O)C=1C=2C=CC(=O)NC=2C(O)=CC=1)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 Chemical compound F.O([C@H]1CC[C@@H](CC1)N(CCCOCCCCCCNC[C@H](O)C=1C=2C=CC(=O)NC=2C(O)=CC=1)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 CNLYMTUKZNDEKW-RGHVVQLISA-N 0.000 claims 1
- SILWREKWJOTGHG-RXCVGROASA-N F.O([C@H]1CC[C@@H](CC1)N(CCOC=1C=CC(CNC[C@H](O)C=2C=3C=CC(=O)NC=3C(O)=CC=2)=CC=1)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 Chemical compound F.O([C@H]1CC[C@@H](CC1)N(CCOC=1C=CC(CNC[C@H](O)C=2C=3C=CC(=O)NC=3C(O)=CC=2)=CC=1)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 SILWREKWJOTGHG-RXCVGROASA-N 0.000 claims 1
- UTKFYKBUXIYENP-IYGAPYOLSA-N F.O([C@H]1CC[C@@H](CC1)N(CCOCCCCCCNC[C@H](O)C=1C=2C=CC(=O)NC=2C(O)=CC=1)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 Chemical compound F.O([C@H]1CC[C@@H](CC1)N(CCOCCCCCCNC[C@H](O)C=1C=2C=CC(=O)NC=2C(O)=CC=1)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 UTKFYKBUXIYENP-IYGAPYOLSA-N 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- WLVUPWOZIUUGMW-RGHVVQLISA-N OC=O.O([C@H]1CC[C@@H](CC1)N(CCCCCCCCCNC[C@H](O)C=1C=2C=CC(=O)NC=2C(O)=CC=1)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 Chemical compound OC=O.O([C@H]1CC[C@@H](CC1)N(CCCCCCCCCNC[C@H](O)C=1C=2C=CC(=O)NC=2C(O)=CC=1)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 WLVUPWOZIUUGMW-RGHVVQLISA-N 0.000 claims 1
- MKUZMLUPXCBRMQ-UZNBJRRRSA-N OC=O.O([C@H]1CC[C@@H](CC1)N(CCCOC=1C=CC(CCNC[C@H](O)C=2C=3C=CC(=O)NC=3C(O)=CC=2)=CC=1)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 Chemical compound OC=O.O([C@H]1CC[C@@H](CC1)N(CCCOC=1C=CC(CCNC[C@H](O)C=2C=3C=CC(=O)NC=3C(O)=CC=2)=CC=1)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 MKUZMLUPXCBRMQ-UZNBJRRRSA-N 0.000 claims 1
- LKLTUAVQAOQHIF-KTZFPCHUSA-N OC=O.O([C@H]1CC[C@@H](CC1)N(CCCOC=1C=CC(CNC[C@H](O)C=2C=3C=CC(=O)NC=3C(O)=CC=2)=CC=1)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 Chemical compound OC=O.O([C@H]1CC[C@@H](CC1)N(CCCOC=1C=CC(CNC[C@H](O)C=2C=3C=CC(=O)NC=3C(O)=CC=2)=CC=1)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LKLTUAVQAOQHIF-KTZFPCHUSA-N 0.000 claims 1
- DDCISFNOIPBCQF-KTZFPCHUSA-N OC=O.O([C@H]1CC[C@@H](CC1)N(CCOC=1C=CC(CCNC[C@H](O)C=2C=3C=CC(=O)NC=3C(O)=CC=2)=CC=1)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 Chemical compound OC=O.O([C@H]1CC[C@@H](CC1)N(CCOC=1C=CC(CCNC[C@H](O)C=2C=3C=CC(=O)NC=3C(O)=CC=2)=CC=1)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 DDCISFNOIPBCQF-KTZFPCHUSA-N 0.000 claims 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 239000013066 combination product Substances 0.000 claims 1
- 229940127555 combination product Drugs 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical group CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines Containing Plant Substances (AREA)
- Quinoline Compounds (AREA)
Claims (17)
1. Spoj formule (I) ili njegove farmaceutski prihvatljive soli ili solvati ili deuterirani derivati:
[image]
naznačen time, što:
• i X i Y predstavljaju atom vodika ili,
• X zajedno s Y formira grupu -CH=CH-, -CH2-O- ili -S, pri čemu je u slučaju -CH2-O- metilenska grupa povezana na atom ugljika u amido supstituentu koji sadrži X, a atom kisika je povezan na atom ugljika u fenilnom prstenu koji sadrži Y,
• R1 i R2 zasebno predstavljaju atom vodika ili C1-4alkilnu grupu,
• R3 predstavlja grupu formule:
[image]
[image]
naznačen time, što:
o Ra predstavlja atom vodika, hidroksi grupu, hidroksimetilnu grupu ili C1-4alkilnu grupu,
o Rb i Rc zasebno predstavljaju tienilnu grupu, fenilnu grupu, benzilnu grupu ili C4-6cikloalkilnu grupu,
o Z predstavlja direktnu vezu ili atom kisika, i
o * predstavlja točku vezivanja R3 na ostatak molekule formule (I),
• A1 i A2 zasebno predstavljaju C1-6alilensku grupu opcionalnu supstituiranu s jednom ili više C1-4alkilnih grupa,
• L predstavlja direktnu vezu, -O-, -NH(CO)-, -(CO)NH- ili -NH(CO)O- grupu, pri čemu je u slučaju -NH(CO)O- atom dušika povezan na W supstituent, a atom kisika je povezan na A2 supstituent; i
• W predstavlja direktnu vezu ili fenilensku grupu koja je opcionalno supstituirana s jednim ili više supstituenata odabranih iz atoma halogena, C1-4alkilne grupe, C1-4 alkoksi grupe i cijano grupe.
2. Spoj prema zahtjevu 1, naznačen time, što X zajedno s Y formira -CH=CH- ili -CH2-O- grupu, poželjno X zajedno s Y formira -CH=CH- grupu.
3. Spoj prema zahtjevu 1 ili 2, naznačen time, što
(a) R1 i R2 zasebno predstavljaju atom vodika ili metilnu grupu; ili
(b) R1 predstavlja atom vodika, a R2 predstavlja metilnu grupu.
4. Spoj prema bilo kojem zahtjevu od 1 do 3, naznačen time, što
(a) R3 predstavlja grupu formule ii), pri čemu je Z atom vodika, a Ra je odabran iz atoma vodika, hidroksi grupe ili metilne grupe; ili
(b) R3 predstavlja atom formule i) pri čemu:
• Ra predstavlja atom vodika, hidroksi grupu ili metilnu grupu, poželjno Ra predstavlja hidroksi grupu,
• Rb i Rc zasebno predstvljaju tienilnu grupu, ciklopentilnu grupu ili fenilnu grupu, poželjno Rb i Rc su oba tienilne grupe.
5. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, što A1 i A2 zasebno predstavljaju C1-6alkilensku grupu opcionalno supstituiranu s jednom ili dvije metilne grupe.
6. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, što L predstavlja -O-, -NH(CO)- ili -NH(CO)O- grupu, pri čemu je u slučaju -NH(CO)-O- atom dušika povezan na W supstituent, a atom kisika je povezan na A2 supstituent.
7. Spoj prema bilo kojem od prethodnih zahtjeva, naznačen time, što W predstavlja fenilensku grupu koja je opcionalno supstituirana s jednim ili dva supstituenta odabrana iz atoma klora, metilne grupe, metoksi grupe i cijano grupe.
8. Spoj prema zahtjevu 1, naznačen time, što
• X zajedno s Y formira -CH=CH- ili -CH2-O- grupu,
• R1 predstavlja atom vodika ili metilnu grupu,
• R2 predstavlja atom vodika ili metilnu grupu,
• R3 predstavlja formulu (i), pri čemu Ra predstavlja hidroksi grupu, a Rb i Rc su zasebno odabrani iz fenilne grupe, ciklopentilne grupe i tienilne grupe, ili Ra predstavlja grupu formule (ii), pri čemu Ra predstavlja metilnu grupu, a Z predstavlja atom kisika,
• A1 i A2 zasebno predstavljaju C1-6 alkilensku grupu koja je opcionalno supstituirana s jednom ili dvije metilne grupe,
• L je odabran iz direktne veze, -O-, -NH(CO)- i -NH(CO)O- grupa i
• W predstavlja direktnu vezu ili fenilensku grupu koja je opcionalno supstituirana s jednim ili dva supstituenta odabrana iz atoma klora, atoma fluora, metoksi grupe i cijano grupe.
9. Spoj prema zahtjevu 8, naznačen time, što
• X zajedno s Y formira -CH=CH- grupu
• R1 predstavlja atom vodika,
• R2 predstavlja atom vodika ili metilnu grupu,
• R3 predstavlja grupu formule (i), pri čemu Ra predstavlja hidroksi grupu, a Rb i Rc su oboje tienilna grupa,
• A1 i A2 zasebno predstavljaju C1-6 alkilensku grupu koja je opcionalno supstituirana s jednom ili dvije metilne grupe,
• L je odabran iz direktne veze, -O-, -NH(CO)- i -NH(CO)O- grupa i
• W predstavlja direktnu vezu ili fenilensku grupu koja je opcionalno supstituirana s jednim ili dva supstituenta odabrana iz atoma klora, metoksi grupe i cijano grupe.
10. Spoj prema zahtjevu 9, naznačen time, što
(a) R2 predstavlja atom vodika, L je odabran iz -O-, -NH(CO)- i -NH(CO)O- grupe, a W predstavlja fenilensku grupu koja je supstituirana s jednim ili dva supstituenta odabrana iz atoma klora, metoksi grupe i cijano grupe ili
(b) R2 predstavlja atom vodika, L je odabran iz -O-, -NH(CO)- i -NH(CO)O- grupe, a W predstavlja fenilensku grupu koja je supstituirana s dva supstituenta odabrana iz atoma klora, metoksi grupe i cijano grupe.
11. Spoj prema zahtjevu 1, koji je
Mravlja kiselina -trans-4-[(9-{[(2R)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrokvinolin-5-il)etil]amino} nonil) (metil)amino]cikloheksil hidroksi(di-2-tienil)acetat (2:1);
Mravlja kiselina -trans-4-[{2-[4-(2-{[(2R)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrokvinolin-5-il)etil] amino}etil) fenoksi]etil}(metil)amino]cikloheksil hidroksi(di-2-tienil) acetat (1:1);
Mravlja kiselina -trans-4-[{3-[4-(2-{[(2R)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrokvinolin-5-il)etil]amino} etil) fenoksi]propil}(metil)amino]cikloheksil hidroksi(di-2-tienil) acetat (1:1);
trans-4-[{2-[(6-{[(2R)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrokvinolin-5-il)-etil]amino}heksil)oksi]etil}(metil)amino]cikloheksil hidroksi(di-2-tienil)-acetat hidrofluorid;
trans-4-[{3-[(6-{[(2R)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrokvinolin-5-il)-etil]amino}heksil)oksi]propil}(metil)amino]cikloheksil hidroksi(di-2-tienil)-acetat hidrofluorid;
Mravlja kiselina -trans-4-[{3-[4-({[(2R)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrokvinolin-5-il)etil]amino} metil) fenoksi]propil}(metil)amino]cikloheksil hidroksi(di-2-tienil)acetat (1:1);
trans-4-[{2-[4-({[(2R)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrokvinolin-5-il)-etil]amino}metil)fenoksi]etil}(metil)amino]cikloheksil hidroksi(di-2-tienil)acetat hidrofluorid;
trans-4-[{3-[4-(2-{[(2R)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrokvinolin-5-il)etil]amino}propil)fenoksi]propil}(metil)amino]cikloheksil hidroksi(di-2-tienil)acetat hidrofluorid;
trans-4-((3-(2-kloro-4-(((2R)-2hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrokvinolin-5-il)etilamino)metil)-5-metoksifenilamino)-3-oksopropil)(metil)amino)-cikloheksil hidroksi(di-2-tienil)acetat hidrofluorid;
trans-4-((3-(2-kloro-4-(((2R)-2hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrokvinolin-5-il)etilamino)metil)fenilamino)-3-oksopropil)(metil)amino)-cikloheksil hidroksi(di-2-tienil)acetat hidrofluorid;
trans-4-[{3-[2-kloro-4-({[(2R)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrokvinolin-5-il)etil]amino}metil)-5-metoksifenoksi]propil}(metil)amino]cikloheksil-hidroksi(di-2-tienil)acetat hidrofluorid;
trans-4-[{2-[({[2-kloro-4-({[(2R)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidro-kvinolin-5-il)etil]amino}metil)-5-metoksifenil]amino}karbonil)oksi]etil}-(metil)amino]-cikloheksilhidroksi(di-2-tienil)acetat hidrofluorid;
trans-4-[(3-{[2-kloro-4-({[(2R)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrokvinolin-5-il)etil)amino}metil)-5-metoksifenil]amino}-3-oksopropil)(metil)amino]-1-metilcikloheksil hidroksi(di-2-tienil)acetat,
trans-4-[(3-{[4-({[(2R)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrokvinolin-5-il)etil)amino}metil)fenil]amino}-3-oksopropil)(metil)amino]cikloheksil hidroksi(di-2-tienil)acetat hidrofluorid (1:2),
trans-4-[(4-{[2-kloro-4-({[(2R)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrokvinolin-5-il)etil)amino}metil)-5-metoksifenil]amino}-4-oksobutil)(metil)amino]-cikloheksil hidroksi(di-2-tienil)acetat,
-trans-4-[(3-{[2-fluoro-4-({[(2R)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrokvinolin-5-il)etil)amino}metil)-5-metoksifenil]amino}-3-oksopropil)(metil)amino]-cikloheksil hidroksi(di-2-tienil)acetat,
trans-4-[(3-{[4-({[(2R)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrokvinolin-5-il)etil)amino}metil)-3-metoksifenil]amino}-3-oksopropil)(metil)amino]-cikloheksil hidroksi(di-2-tienil)acetat hidrofluorid (1:2),
trans-4-[(3-{[2,5-difluoro-4-({[(2R)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrokvinolin-5-il)etil)amino}metil)fenil]amino}-3-oksopropil)(metil)amino]-cikloheksil hidroksi(di-2-tienil)acetat hidrofluorid (1:2),
trans-4-[(3-{[2-fluoro-4-({[(2R)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrokvinolin-5-il)etil)amino}metil)fenil]amino}-3-oksopropil)(metil)amino]cikloheksil hidroksi(di-2-tienil)acetat hidrofluorid (1:2),
trans-4-[(3-{[2-kloro-4-(2-{[(2R)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrokvinolin-5-il)etil)amino}etil)-5-metoksifenil]amino}-3-oksopropil)(metil)amino]cikloheksil hidroksi(di-2-tienil)acetat hidrofluorid (1:2),
trans-4-[{3-[2-kloro-4-(2-{[(2R)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrokvinolin-5-il)etil)amino}etil)-5-metoksifenoksi]propil}(metil)-amino]cikloheksil hidroksi(di-2-tienil)acetat hidrofluorid (1:2),
trans-4-[{2-[({[2-cijano-4-({[(2R)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrokvinolin-5-il)etil]amino}metil)-5-metoksifenil]amino}karbonol)-oksi]etil}(metil)amino]cikloheksil hidroksi(di-2-tienil)acetat hidrofluorid (1:2),
trans-4-[{2-[({[2,5-difluoro-4-({[(2R)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrokvinolin-5-il)etil]amino}metil)fenil]amino}karbonol)-oksi]etil}-(metil)amino]cikloheksil hidroksi(di-2-tienil)acetat hidrofluorid (1:2),
trans-4-[(3-{[2-kloro-4-({[(2R)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrokvinolin-5-il)etil)amino}metil)-5-metoksifenil]amino}-2,2-dimetil-3-oksopropil)(metil)amino]cikloheksil hidroksi(di-2-tienil)acetat,
trans-4-[{4-[2-kloro-4-({[(2R)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrokvinolih-5-il)etil]amino}metil)-5-metoksifenoksi]butil}(metil)amino]cikloheksil hidroksi(di-2-tienil)acetat hidrofluorid (1:2),
trans-4-[{2-[({[2-kloro-4-({[(2R)-2-hidroksi-2-(5-hidroksi-3-okso-3,4-dihidro-2H-1,4-benzoksazin-8-il)etil]amino}metil)-5-metoksifenil]amino}karbonil)oksi]-etil}(metil)amino]cikloheksil hidroksi(di-2-tienil)acetat,
trans-4-[(9-{[(2R)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrokvinolin-5-il)etil]-amino}nonil)(metil)amino]cikloheksil 9-metil-9H-ksanten-9-karboksilat,
trans-4-[{2-[({[2-kloro-4-({[(2R)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidro-kvinolin-5-il)etil]amino}metil)-5-metoksifenil]amino}karbonil)oksi]etil}-(metil)-amino]cikloheksil (2R)-ciklopentil(hidroksi)fenilacetat, i
trans-4-[{2-[({[2-kloro-4-({[(2R)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidro-kvinolin-5-il)etil]amino}metil)-5-metoksifenil]amino}karbonil)oksi]etil}-(metil)-amino]cikloheksil (2S)-ciklopentil(hidroksi)2-tienilacetat,
ili njegove farmaceutski prihvatljive soli ili solvati ili deuterirani derivati.
12. Spoj prema zahtjevu 11, koji je trans-4-((3-(2-kloro-4-(((2R)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidrokvinolin-5-il)etilamino)metil)-5-metoksifenilamino)-3-oksopropil)(metil)amino)-cikloheksil hidroksi(di-2-tienil)acetat
hidrofluorid ili njegovi solvati ili deuterirani derivati.
13. Spoj prema zahtjevu 11, koji je -trans-4-[{2-[({[2-kloro-4-({[(2R)-2-hidroksi-2-(8-hidroksi-2-okso-1,2-dihidro kvinolin-5-il)etil]amino}metil)-5-metoksifenil]amino}karbonil)oksi]etil}-(metil)amino]-cikloheksilhidroksi(di-2-tienil)acetat hidrofluorid ili njegovi solvati ili deuterirani derivati.
14. Spoj prema bilo kojem zahtjevu od 1 do 13 za primjenu u liječenju ljudskog ili životinjskog organizma pomoću terapije.
15. Spoj prema bilo kojem zahtjevu od 1 do 13 za primjenu u liječenju bolesti odabrane iz plućnih bolesti, glaukoma, neuroloških poremećaja, srčanih poremećaja, upalnih i gastrointestinalnih poremećaja.
16. Farmaceutski pripravak koji se sastoji od spoja kako je definirano u bilo kojem zahtjevu od 1 do 13 asociranog s farmaceutski prihvatljivim otapalom ili nosačem.
17. Kombinirani proizvod koji se sastoji od (i) spoja prema bilo kojem zahtjevu od 1 do 13 i (ii) drugog spoja odabranog iz kortikosteroida i inhibitora PDE4.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10382118A EP2386555A1 (en) | 2010-05-13 | 2010-05-13 | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
| US36504510P | 2010-07-16 | 2010-07-16 | |
| EP11720386.9A EP2569308B1 (en) | 2010-05-13 | 2011-05-13 | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
| PCT/EP2011/002376 WO2011141180A1 (en) | 2010-05-13 | 2011-05-13 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170307T1 true HRP20170307T1 (hr) | 2017-04-21 |
Family
ID=42646365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20170307TT HRP20170307T1 (hr) | 2010-05-13 | 2017-02-23 | NOVI DERIVATI CIKLOHEKSILAMINA KOJI POSJEDUJU DJELOVANJA AGONISTA ß2 ADRENERGIČKOG RECEPTORA I ANTAGONISTA M3 MUSKARINSKOG RECEPTORA |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US9643961B2 (hr) |
| EP (2) | EP2386555A1 (hr) |
| JP (1) | JP5851489B2 (hr) |
| KR (1) | KR101756497B1 (hr) |
| CN (1) | CN102892765B (hr) |
| AR (1) | AR081387A1 (hr) |
| AU (1) | AU2011252337C1 (hr) |
| BR (1) | BR112012026570A2 (hr) |
| CA (1) | CA2799099C (hr) |
| CL (1) | CL2012003171A1 (hr) |
| CO (1) | CO6592031A2 (hr) |
| CR (1) | CR20120574A (hr) |
| CY (1) | CY1118352T1 (hr) |
| DK (1) | DK2569308T3 (hr) |
| EA (1) | EA022358B1 (hr) |
| EC (1) | ECSP12012213A (hr) |
| ES (1) | ES2613355T3 (hr) |
| GT (1) | GT201200307A (hr) |
| HR (1) | HRP20170307T1 (hr) |
| HU (1) | HUE033244T2 (hr) |
| IL (1) | IL222538A (hr) |
| LT (1) | LT2569308T (hr) |
| ME (1) | ME02675B (hr) |
| MX (1) | MX2012012897A (hr) |
| MY (1) | MY171899A (hr) |
| NZ (1) | NZ602556A (hr) |
| PE (1) | PE20130215A1 (hr) |
| PL (1) | PL2569308T3 (hr) |
| PT (1) | PT2569308T (hr) |
| RS (1) | RS55725B1 (hr) |
| SG (1) | SG185007A1 (hr) |
| SI (1) | SI2569308T1 (hr) |
| SM (1) | SMT201700022B (hr) |
| TW (1) | TWI526442B (hr) |
| UY (1) | UY33362A (hr) |
| WO (1) | WO2011141180A1 (hr) |
| ZA (1) | ZA201207031B (hr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
| ITRM20110083U1 (it) | 2010-05-13 | 2011-11-14 | De La Cruz Jose Antonio Freire | Piastra per la costruzione di carrelli per aeroplani |
| EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| EP2592077A1 (en) * | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| WO2014083171A1 (en) | 2012-11-30 | 2014-06-05 | Harmonic Pharma | Natural compounds for use in the treatment of beta-2 adrenergic receptor related diseases |
| CN105142673B8 (zh) | 2012-12-18 | 2018-02-16 | 阿尔米雷尔有限公司 | 具有β2肾上腺素能激动剂及M3毒蕈碱拮抗剂活性的新型环己基和奎宁环基氨基甲酸酯衍生物 |
| TWI643853B (zh) * | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
| TW201440768A (zh) * | 2013-02-27 | 2014-11-01 | Almirall Sa | 雙毒蕈鹼拮抗劑-β2腎上腺素促效劑複合物及皮質類固醇之組合物 |
| TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽 |
| TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有ｍａｂａ化合物和皮質類固醇之組合 |
| EP3077385B1 (en) * | 2013-12-05 | 2017-10-04 | Chiesi Farmaceutici S.p.A. | Heteroaryl derivatives for the treatment of respiratory diseases |
| KR20160085350A (ko) * | 2013-12-05 | 2016-07-15 | 키에시 파르마슈티시 엣스. 피. 에이. | 호흡기 질환의 치료를 위한 벤즈히드릴 유도체 |
| CA3193201A1 (en) * | 2014-05-06 | 2015-11-12 | Anthony G. Visco | Methods of treating or preventing preterm labor |
| AU2015274801B2 (en) | 2014-06-09 | 2020-10-15 | Biometry Inc. | Low cost test strip and method to measure analyte |
| US11175268B2 (en) | 2014-06-09 | 2021-11-16 | Biometry Inc. | Mini point of care gas chromatographic test strip and method to measure analytes |
| TW201617343A (zh) * | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物 |
| TWI703138B (zh) * | 2015-02-12 | 2020-09-01 | 義大利商吉斯藥品公司 | 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物 |
| CN114859028A (zh) | 2016-07-19 | 2022-08-05 | 生物统计股份有限公司 | 使用批量可校准测试条测量分析物的方法和系统 |
| WO2020244452A1 (zh) * | 2019-06-06 | 2020-12-10 | 中国医药研究开发中心有限公司 | 具有β 2受体激动及M受体拮抗活性的杂环衍生物及其医药用途 |
| US20240208951A1 (en) * | 2021-02-12 | 2024-06-27 | Gbr Laboratories Private Limited | A process for preparing navafenterol and intermediates thereof |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT7920688V0 (it) | 1979-02-05 | 1979-02-05 | Chiesi Paolo Parma | Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore. |
| DE3274065D1 (de) | 1981-07-08 | 1986-12-11 | Draco Ab | Powder inhalator |
| IT1212742B (it) | 1983-05-17 | 1989-11-30 | Dompe Farmaceutici Spa | Derivati dibenzo [1,4]diazepinonici pirido [1,4] benzodiazepinonici,pirido [1,5] benzodiazepinonici e loro attivita' farmacologica |
| US4570630A (en) | 1983-08-03 | 1986-02-18 | Miles Laboratories, Inc. | Medicament inhalation device |
| ATE25966T1 (de) | 1983-09-26 | 1987-04-15 | Magis Farmaceutici | Aminocyclohexanol-derivate mit expektoranter wirkung, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen. |
| FI69963C (fi) | 1984-10-04 | 1986-09-12 | Orion Yhtymae Oy | Doseringsanordning |
| DE3927170A1 (de) | 1989-08-17 | 1991-02-21 | Boehringer Ingelheim Kg | Inhalator |
| EP0416925A3 (en) | 1989-09-07 | 1991-09-25 | Glaxo Group Limited | Use of 4-hydroxy-alpha 1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol or its salts in the treatment of allergy and inflammation |
| IT1237118B (it) | 1989-10-27 | 1993-05-18 | Miat Spa | Inalatore multidose per farmaci in polvere. |
| US5201308A (en) | 1990-02-14 | 1993-04-13 | Newhouse Michael T | Powder inhaler |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| SG45171A1 (en) | 1990-03-21 | 1998-01-16 | Boehringer Ingelheim Int | Atomising devices and methods |
| GB9015522D0 (en) | 1990-07-13 | 1990-08-29 | Braithwaite Philip W | Inhaler |
| WO1992003175A1 (en) | 1990-08-11 | 1992-03-05 | Fisons Plc | Inhalation device |
| DE4027391A1 (de) | 1990-08-30 | 1992-03-12 | Boehringer Ingelheim Kg | Treibgasfreies inhalationsgeraet |
| GB9020051D0 (en) | 1990-09-13 | 1990-10-24 | Pfizer Ltd | Muscarinic receptor antagonists |
| DE69132850T2 (de) | 1990-09-26 | 2002-05-29 | Pharmachemie Bv | Wirbelkammer-Pulverinhalator |
| GB9026025D0 (en) | 1990-11-29 | 1991-01-16 | Boehringer Ingelheim Kg | Inhalation device |
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| DE4239402A1 (de) | 1992-11-24 | 1994-05-26 | Bayer Ag | Pulverinhalator |
| KR0163472B1 (ko) | 1992-12-18 | 1998-11-16 | 에릭 에스. 딕커 | 분말 약품용 흡입기 |
| ATE250439T1 (de) | 1995-04-14 | 2003-10-15 | Smithkline Beecham Corp | Dosierinhalator für salmeterol |
| CZ294782B6 (cs) | 1995-06-21 | 2005-03-16 | Sofotec Gmbh & Co. Kg | Inhalátor pro prášková léčiva |
| DE19536902A1 (de) | 1995-10-04 | 1997-04-10 | Boehringer Ingelheim Int | Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung |
| AU4248597A (en) | 1996-09-06 | 1998-03-26 | Merck & Co., Inc. | Methods and compositions for treating preterm labor |
| JPH1171331A (ja) * | 1997-08-27 | 1999-03-16 | Tokyo Tanabe Co Ltd | アミノシクロアルキルメタノール化合物 |
| SE9704644D0 (sv) | 1997-12-12 | 1997-12-12 | Astra Ab | New use |
| US6673908B1 (en) | 1999-02-22 | 2004-01-06 | Nuvelo, Inc. | Tumor necrosis factor receptor 2 |
| BR0013469B1 (pt) | 1999-08-20 | 2011-01-25 | amidas aromáticas heterocìclicas fungicidas, composição fungicida compreendendo as mesmas, bem como método para o controle ou a prevenção de infestação fúngica. | |
| CA2398182C (en) * | 2000-01-31 | 2007-03-13 | Pfizer Products Inc. | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes |
| CA2415468A1 (en) * | 2000-07-11 | 2003-01-10 | Yoshio Ogino | Ester derivatives |
| AU2002238471B2 (en) | 2000-12-28 | 2007-06-28 | Almirall, S.A. | Quinuclidine derivatives and their use as M3 antagonists |
| DE10129703A1 (de) | 2001-06-22 | 2003-01-02 | Sofotec Gmbh & Co Kg | Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren |
| DE10202940A1 (de) | 2002-01-24 | 2003-07-31 | Sofotec Gmbh & Co Kg | Patrone für einen Pulverinhalator |
| ES2195785B1 (es) | 2002-05-16 | 2005-03-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| ES2211344B1 (es) | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| EP1615881A2 (en) | 2003-04-01 | 2006-01-18 | Theravance, Inc. | Diarylmethyl and related compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| US7358244B2 (en) | 2003-05-28 | 2008-04-15 | Theravance, Inc. | Azabicycloalkane compounds |
| ES2232306B1 (es) | 2003-11-10 | 2006-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| WO2005080375A1 (en) | 2004-02-13 | 2005-09-01 | Theravance, Inc. | Crystalline form of a biphenyl compound |
| DE102004024453A1 (de) | 2004-05-14 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen |
| ES2251866B1 (es) | 2004-06-18 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| ES2251867B1 (es) | 2004-06-21 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| EP1616592B9 (en) | 2004-07-16 | 2011-02-02 | Almirall, S.A. | Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge for use with this inhaler |
| JP2008510014A (ja) | 2004-08-16 | 2008-04-03 | セラヴァンス， インコーポレーテッド | β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物 |
| TWI374883B (en) | 2004-08-16 | 2012-10-21 | Theravance Inc | Crystalline form of a biphenyl compound |
| US7569586B2 (en) | 2004-08-16 | 2009-08-04 | Theravance, Inc. | Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity |
| US7994211B2 (en) | 2005-08-08 | 2011-08-09 | Argenta Discovery Limited | Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses |
| GB0602778D0 (en) | 2006-02-10 | 2006-03-22 | Glaxo Group Ltd | Novel compound |
| NZ570693A (en) | 2006-03-20 | 2011-02-25 | Pfizer Ltd | Amine derivatives |
| TW200811104A (en) | 2006-04-25 | 2008-03-01 | Theravance Inc | Crystalline forms of a dimethylphenyl compound |
| GB0613154D0 (en) | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| GB0702384D0 (en) * | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | Chemical compounds |
| WO2008017827A2 (en) | 2006-08-08 | 2008-02-14 | Argenta Discovery Limited | Azole and thiazole derivatives and their uses |
| EP1894568A1 (en) | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
| AU2007303909A1 (en) | 2006-10-04 | 2008-04-10 | Pfizer Limited | Sulfonamide derivatives as adrenergic agonists and muscarinic antagonists |
| GB0700972D0 (en) | 2007-01-18 | 2007-02-28 | Imp Innovations Ltd | Treatment of inflammatory disease |
| WO2008096129A1 (en) | 2007-02-07 | 2008-08-14 | Argenta Discovery Ltd | Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors |
| GB0702413D0 (en) | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | New chemical compounds |
| WO2008149110A1 (en) | 2007-06-08 | 2008-12-11 | Argenta Discovery Limited | Bicyclor [2.2.1] hept-7-ylamine derivatives and their use in the treatment of diseases and conditions in which m3 muscarinic receptor activity and beta-adrenergic activity are implicated |
| UY31235A1 (es) | 2007-07-21 | 2009-03-02 | Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente | |
| WO2009017813A1 (en) | 2007-08-02 | 2009-02-05 | Teva Pharmaceutical Industries Ltd. | O-desmethyl venlafaxine saccharinate |
| PL2242759T3 (pl) | 2008-02-06 | 2013-06-28 | Astrazeneca Ab | Związki |
| CN101544572B (zh) | 2008-03-26 | 2013-03-20 | 连云港恒邦医药科技有限公司 | 一种氨溴索衍生物及其制备方法 |
| GB0808708D0 (en) | 2008-05-13 | 2008-06-18 | Astrazeneca Ab | New compounds 274 |
| US8263623B2 (en) | 2008-07-11 | 2012-09-11 | Pfizer Inc. | Triazol derivatives useful for the treatment of diseases |
| WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
| CA2758505C (en) | 2009-04-23 | 2017-03-07 | Theravance, Inc. | Diamide compounds having muscarinic receptor antagonist and .beta.2 adrenergic receptor agonist activity |
| JP5379224B2 (ja) | 2009-04-30 | 2013-12-25 | 帝人ファーマ株式会社 | 四級アンモニウム塩化合物 |
| GB0913345D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | New combination 802 |
| ITRM20110083U1 (it) | 2010-05-13 | 2011-11-14 | De La Cruz Jose Antonio Freire | Piastra per la costruzione di carrelli per aeroplani |
| EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
| AR083115A1 (es) | 2010-09-30 | 2013-01-30 | Theravance Inc | Sales oxalato cristalinas de un compuesto diamida |
| GB201021979D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | New compound |
| GB201021992D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | Compound |
| CA2838777C (en) | 2011-06-10 | 2019-04-30 | Chiesi Farmaceutici S.P.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| HUE027000T2 (en) | 2011-06-10 | 2016-08-29 | Chiesi Farm Spa | Compounds with muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| SI2776038T1 (en) | 2011-11-11 | 2018-06-29 | Gilead Apollo, Llc | ACC INHIBITORS AND THEIR USE |
| WO2013068875A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | 2-thiopyrimidinones |
| EP2592077A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| UA116622C2 (uk) | 2011-11-11 | 2018-04-25 | Аллерган, Інк. | Похідні 4-прегенен-11ss-17-21-тріол-3,20-діону для лікування хвороб очей |
| EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| RU2661877C2 (ru) | 2012-12-06 | 2018-07-20 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2-адренергических рецепторов |
| LT3345904T (lt) | 2012-12-06 | 2020-09-25 | Chiesi Farmaceutici S.P.A. | Junginiai, pasižymintys muskarininių receptorių atžvilgiu antagonistinių ir beta-2-adrenerginių receptorių atžvilgių antagonistiniu aktyvumu |
| CN105142673B8 (zh) | 2012-12-18 | 2018-02-16 | 阿尔米雷尔有限公司 | 具有β2肾上腺素能激动剂及M3毒蕈碱拮抗剂活性的新型环己基和奎宁环基氨基甲酸酯衍生物 |
| TW201440768A (zh) | 2013-02-27 | 2014-11-01 | Almirall Sa | 雙毒蕈鹼拮抗劑-β2腎上腺素促效劑複合物及皮質類固醇之組合物 |
| TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
| TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有ｍａｂａ化合物和皮質類固醇之組合 |
| TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽 |
| TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物 |
-
2010
- 2010-05-13 EP EP10382118A patent/EP2386555A1/en not_active Withdrawn
-
2011
- 2011-04-28 UY UY33362A patent/UY33362A/es unknown
- 2011-05-09 TW TW100116155A patent/TWI526442B/zh not_active IP Right Cessation
- 2011-05-11 AR ARP110101622A patent/AR081387A1/es active IP Right Grant
- 2011-05-13 DK DK11720386.9T patent/DK2569308T3/da active
- 2011-05-13 ES ES11720386.9T patent/ES2613355T3/es active Active
- 2011-05-13 SI SI201131037A patent/SI2569308T1/sl unknown
- 2011-05-13 PT PT117203869T patent/PT2569308T/pt unknown
- 2011-05-13 HU HUE11720386A patent/HUE033244T2/hu unknown
- 2011-05-13 NZ NZ602556A patent/NZ602556A/xx not_active IP Right Cessation
- 2011-05-13 EP EP11720386.9A patent/EP2569308B1/en active Active
- 2011-05-13 CN CN201180023678.6A patent/CN102892765B/zh not_active Expired - Fee Related
- 2011-05-13 AU AU2011252337A patent/AU2011252337C1/en not_active Ceased
- 2011-05-13 BR BR112012026570A patent/BR112012026570A2/pt not_active Application Discontinuation
- 2011-05-13 JP JP2013509473A patent/JP5851489B2/ja not_active Expired - Fee Related
- 2011-05-13 MX MX2012012897A patent/MX2012012897A/es active IP Right Grant
- 2011-05-13 WO PCT/EP2011/002376 patent/WO2011141180A1/en active Application Filing
- 2011-05-13 PL PL11720386T patent/PL2569308T3/pl unknown
- 2011-05-13 LT LTEP11720386.9T patent/LT2569308T/lt unknown
- 2011-05-13 PE PE2012002162A patent/PE20130215A1/es active IP Right Grant
- 2011-05-13 SG SG2012078689A patent/SG185007A1/en unknown
- 2011-05-13 KR KR1020127029561A patent/KR101756497B1/ko active IP Right Grant
- 2011-05-13 RS RS20170180A patent/RS55725B1/sr unknown
- 2011-05-13 CA CA2799099A patent/CA2799099C/en active Active
- 2011-05-13 ME MEP-2017-18A patent/ME02675B/me unknown
- 2011-05-13 EA EA201201541A patent/EA022358B1/ru not_active IP Right Cessation
- 2011-05-13 MY MYPI2012700932A patent/MY171899A/en unknown
-
2012
- 2012-09-19 ZA ZA2012/07031A patent/ZA201207031B/en unknown
- 2012-10-03 EC ECSP12012213 patent/ECSP12012213A/es unknown
- 2012-10-18 IL IL222538A patent/IL222538A/en active IP Right Grant
- 2012-11-12 CL CL2012003171A patent/CL2012003171A1/es unknown
- 2012-11-12 GT GT201200307A patent/GT201200307A/es unknown
- 2012-11-13 CR CR20120574A patent/CR20120574A/es unknown
- 2012-11-13 CO CO12203219A patent/CO6592031A2/es active IP Right Grant
-
2016
- 2016-03-14 US US15/068,926 patent/US9643961B2/en active Active
- 2016-12-19 CY CY20161101314T patent/CY1118352T1/el unknown
-
2017
- 2017-01-16 SM SM201700022T patent/SMT201700022B/it unknown
- 2017-02-23 HR HRP20170307TT patent/HRP20170307T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170307T1 (hr) | NOVI DERIVATI CIKLOHEKSILAMINA KOJI POSJEDUJU DJELOVANJA AGONISTA ß2 ADRENERGIČKOG RECEPTORA I ANTAGONISTA M3 MUSKARINSKOG RECEPTORA | |
| HRP20170638T1 (hr) | MODULATORI RETINOIDNIMA SRODNOG SIROČETA RECEPTORA γ (ROR-γ), NAMIJENJENI UPOTREBI U LIJEČENJU AUTOIMUNIH I PROTUUPALNIH BOLESTI | |
| HRP20161547T1 (hr) | Derivati 5-fluor-n-(piridin-2-il)piridin-2-amina koji sadrže sulfoksiminsku skupinu | |
| JP2013526494A5 (hr) | ||
| AR037748A1 (es) | Glicinamidas como inhibidores del factor xa | |
| RS54165B1 (en) | NEW LIGANDS FOR THE ESTROGENIC RECEPTOR | |
| RS53244B (en) | 1`-SUBSTITUTED-CARB-NUCLEOSIDE PROTECTION FOR ANTI-VIRUS TREATMENT | |
| RU2008125196A (ru) | Новые производные тиофена | |
| AR037092A1 (es) | Compuestos que contienen lactama y derivados de los mismos como inhibidores del factor xa | |
| HRP20100724T1 (hr) | Supstituirani biciklički derivati pirimidona | |
| TR201904655T4 (tr) | Piridilaminoasetik asit bileşiği. | |
| JP2011519854A5 (hr) | ||
| JP2014521625A5 (hr) | ||
| RS54708B1 (en) | ARYLETINYL DERIVATIVES | |
| HRP20100541T1 (hr) | Derivati bifeniloksioctene kiseline za liječenje respiratornih bolesti | |
| RU2014113679A (ru) | N-(2-амино-6,6-дифтор-4,4а,5,6,7,7а-гексагидро-циклопента[e][1,3]оксазин-4-ил)-фенил)-амиды в качестве ингибиторов бета-секретазы 1 | |
| HRP20070577T4 (hr) | Derivati kinazolinona koji se mogu upotrijebiti kao antagonisti vaniloida | |
| MX2010009401A (es) | Forma cristalina de derivado de fenilamino pirimidina. | |
| AR037644A1 (es) | Aminometilos sustituidos como inhibidores del factor xa | |
| JP2011529037A5 (hr) | ||
| WO2006043149A3 (en) | Novel dicarboxylic acid derivatives | |
| MY142773A (en) | Substituted 4-alkyl-and-alkanoyl-piperidine derivatives and their use as neurokinin antagonists | |
| JP2016505582A5 (hr) | ||
| HRP20100246T1 (hr) | 2-(piridin-2-il)-pirimidini i njihova primjena za kontrolu patogenih gljiva | |
| EA200701879A1 (ru) | Замещённые производные оксадиазаспиро [5.5] ундеканона и их применение в качестве антагонистов нейрокинина |